A Newly Recognized DXA Confounder: The Potassium-Binding Medication Sodium Zirconium Cyclosilicate.

OBJECTIVE

Radio-dense artifacts, including contrast material, alter dual-energy X-ray absorptiometry (DXA) results. An apparent diffuse artifact was identified during spine DXA acquisition in a patient without recent radiographic procedures. The patient reported taking sodium zirconium cyclosilicate (SZC; Lokelma®) 10 g 1 h before scanning. SZC is a potassium-binding agent recently marketed to treat hyperkalemia. Given the chemical composition, we hypothesized that SZC may alter DXA results. This study evaluated if SZC affects DXA results using an encapsulated spine and a total body phantom.

METHODOLOGY

An encapsulated spine and total body phantom were scanned using a Lunar iDXA. Each phantom was scanned 5 times serially without repositioning in 5 configurations: (1) Bare, (2) 45 mL tap water, (3) 90 mL water, (4) 10 g SZC in 45 mL of water, and (5) 30 g SZC in 90 mL of water. Water and SZC was contained in plastic quart bags, folded, and placed over L2-3 on the spine phantom and flat over the pelvis/torso of the total body phantom.

RESULTS

Tap water did not change spine phantom measurements, but did increase (p < 0.05) total body phantom lean mass 46 g and 89 g with 45 mL and 90 mL, respectively. SZC 10 g or 30 g increased (p < 0.001) L2 and L3 bone mineral density (BMD) 18%-110%, mean 0.295 and 0.924 g/cm, respectively, while L1 and L4 BMD was statistically, but not clinically, altered by <0.010 g/cm. A dose-dependent change (p < 0.001) in total body phantom trunk measurements was demonstrated. The 10 g dose increased lean mass 16.8% and BMC 1%; fat mass was reduced 16.6%, while 30 g increased lean 41.9%, BMC 3.2%, and decreased fat 42.9%.

CONCLUSION

SZC confounds BMD and body composition phantom measurements. It is likely that SZC alters DXA results in humans. DXA technologists and interpreters should be aware of this confounder.